Ching-Chiung Wang ph. D., Director, Graduate Institute of Pharmacognosy, Taipei Medical University, recently provided the following health tips. Dr. Wang Ching-Chiung is the scientific advisory board member of Infinitus Health Products (International) Company Limited.
Heart, liver, spleen, lungs and kidneys are the five primary organs we usually care the most, but we often think too little of the importance of gastrointestinal health. We tolerate stomach ache, diarrhea, or even constipation. However, a latest research by Magnus Simrén, a gastroenterologist from the University of Gothenburg, has been published in Gastroenterology Journal, and it revealed the following: Out of every ten adults in the world, there are four of them who have certain degree of functional gastrointestinal diseases. Therefore, gastrointestinal health problems are very common, and should not be neglected!
We all know the stomach and intestines are the primary organs that digest and absorb nutrients, then excrete the toxins. In addition to that, these organs are also crucial to human immunity. 80% of human immunocytes are produced in the gastrointestinal mucosa, and 70% of human immunocytes can be found in the intestines. Therefore, gastrointestinal health determines whether or not our immunity is functioning properly.
The importance and urgency of improving our immunity during the pandemic are obvious. The question is, how can the general public improve their gastrointestinal immunity?
First of all, having a regular and abstinent diet is important. An irregular eating habit has negative impacts on gastrointestinal functions, which will eventually result in weakened immunity. In addition, we should avoid food that is too cold, too hot or irritating to the digestive system, to protect the gastrointestinal mucosa from possible damages. Besides, we can also eat food that helps nurture gastric health. Take lion’s mane mushroom for example, the polysaccharide in it has been found effective in repairing damaged gastric mucosa. It is even used in treating Helicobacter pylori infection with 90% efficacy rate, reducing gastric inflammation and promoting overall gastric health.
Sufficient sleep is also essential. When our body is fatigued, and our stomach and intestines are not well rested, the barrier function may be weakened, making our body vulnerable to external threats, such as viruses and bacteria.
In addition to the healthy lifestyle suggested above, you can also take probiotic supplements to regulate the balance of the gut microbiota. Viability, quantity, strains and combination are key factors we should consider when choosing the right probiotic supplement. Only sufficient amounts of viable probiotics can have the positive effects on our intestinal health.
There are numerous kinds of probiotics, but not all of them can survive the gastric acid and bile during the digestive process and “make it” to the intestines. Scientific research has shown that probiotic strains with strong vitality after the stabilization process include Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bi-07 and Rhamnosus HN001. Even when these viable probiotics have “made it” to the intestines, they will still need to be “fed” with prebiotics to ensure the efficacy. Some common prebiotics include inulin and dioligosaccharides.
Improving immunity cannot be done within a day. It requires continuous efforts in our everyday life. Let us replenish probiotics properly, develop a regular healthy diet and manage our sleep schedule from now on!
Infinitus strives to provide high-quality Chinese herbal health products and services to the public. Infinitus organizes various health promotion activities to bring health and happiness to people all over the world. Please visit the website to learn more: https://www.infinitus-int.com
a global leader in the development of innovative healthcare technology, hosts a virtual launch event on October 15 to introduce its brand new A9 and A8 anesthesia systems, which is now available in Europe and other selected regions. This marks Mindray’s entry as a key player in the high-end anesthesia machine market. Click here to watch the event.
“Mindray is committed to improving outcomes by providing all-round safety to patients, clinicians and the environment. We believe these systems are a clear testament to that,” said Ralph Zhao, General Manager of Sales and Marketing, Patient Monitoring and Life Support, Mindray. “Mindray’s new systems feature state-of-the-art technologies that address the needs of clinicians during the entire perioperative period, allowing them to administer accurate, stable and safe anesthesia to patients, while minimizing the risks of human error, reducing workload, and lowering the environmental impact from the operating room.”
Mindray’s new anesthesia systems empower anesthesiologists to ensure comprehensive patient safety throughout the perioperative period, from induction to recovery. Using High Flow Nasal Cannula oxygen (HFNC), Mindray’s new systems extend safe apnoeic time from 8 to up to 30 minutes to help clinicians intubate more easily.
The machines also integrate Automatic Controlled Anesthesia (ACA), a pioneering assistive technology that automatically adjusts fresh gas and vaporizer output to quickly achieve preset target end-tidal agent and inspiratory oxygen concentration, ensuring accurate and stable levels of anesthesia. The technology also helps cut down on workload for clinicians; while reducing cost by minimizing the consumption of gas and agents used throughout the case.
Committed to improving safety, Mindray’s new systems feature ICU-quality ventilation technologies to protect a patient’s respiratory system throughout the perioperative period. Both systems have integrated a Volume Exchanger, an innovative system that delivers precise and reliable ventilation to patients with rapid wash-in and wash-out time. Additionally, Mindray has incorporated powerful protective ventilation toolkits to reduce the incidence of post-operative complications, such as transpulmonary pressure monitoring.
Furthermore, to create a greener operating room, the A9 employs anesthetic gas reduction strategies during surgery. Clinical decision-support tools, such as the Optimizer, AA measurement and AA prediction, help advise clinicians of the most efficient gas flow to reduce waste. It also features an e-AGSS system that monitors the waste gas scavenging flow rate and indicates anomalies – plus switches off in standby to reduce energy consumption.
Designed with deep insights into the clinical workflow of the operating room, the intuitive user interfaces ease the workload of busy and stressed anesthesiologists. An 18.5″ capacitive touchscreen with 360-degree rotation provides intuitive interface and up to 10 customizable profiles for different clinical scenarios or use requirements. Automated pre-use system check helps ensure proper functioning with graphic display of errors, and it can be scheduled any time as needed.
In addition, the machines can be physically connected to many other Mindray devices as a highly integrated anesthesia workstation. It can also seamlessly connect to multiple hospital information systems using Mindray’s flexible integration solution, so caregivers can check on a patient’s status anywhere, anytime.
Learn more: https://www.mindray.com/en/product/a9.html
Shreveport – Willis-Knighton Health System has recently implemented a new device the AccuVein AV400 vein illumination system, which will make taking blood a lot more efficient in all of the nursing units at all all four of the Willis-Knighton hospitals.
The new device uses a beam of light that is projected onto a patient’s arm and will illuminate their peripheral veins making it easier for healthcare professionals to locate veins for venipuncture.
With venipuncture being one of the most common invasive medical procedures worldwide, and with up to one third of attempts to access a vein failing on the first time, the new AccuVein device is set to help improve first-stick attempts immensely at all Willis-Kingston hospitals.
“This is going to be good for the nursing staff, but even better for our patients,” says Georgia Stephens, MSN, RN and patient care coordinator for staff development. “It illuminates the arm so the veins are easy to see. The AccuVein System does not touch the patient. Its use will enhance the comfort and safety of the patient and increase nursing efficiency.”The implementation of the AccuVein system is in accordance with the Willis-Knighton’s commitment to the adoption of technology to enhance patient care and comfort. It is meant to help make sure that all patients, especially ones who are dehydrated, obese, have low body temperature, whose veins roll or who have had frequent venipunctures, receive venipunctures quickly and without unnecessary discomfort.
A Medical Detox Program
Lafayette – The University Hospital and Clinics has recently reestablished its Medical Detoxification Program, which has been closed since February 2012 due to state budget cuts. The 12-bed center is now open and taking patients, which makes it Lafayette’s only hospital-run inpatient medical detox center.
UHC President and CEO Jared Stark said that the facility fulfills a great need in the Lafayette community. “This is yet another former closure that we have brought back to our community. Our goal is to keep this momentum going.”
The voluntary inpatient program will be open to all eligible patients 18 years or older. In order to be eligible, patients must be diagnosed with substance dependance or withdrawal and they must be willing to undergo treatment.
The facility will be managed by Compass Health and is going to provide 24-hour medically supervised evaluation and treatment by trained detox nurses and counseling staff along with physician, pharmacy, testing, dietary and environmental services.It is designed to be the “first step” in a patient’s detox recovery. The program looks to provide a safe, therapeutic experience and minimize the painful effects of withdrawal. The detox protocols usually have a 5-7 day duration, at which point patients will be assisted in transitioning into a more comprehensive facility to complete their recovery.
New Virus-caused Cancer Drug
New Orleans – LSU Health Sciences Center New Orleans released information that reveals a new therapy treatment for preventing the production of lymphoma cancer cells caused by viruses, which are sometimes resistant to typical therapies.
The LSU research team was the first to show that a specialized fat molecule, called sphingolipids, may play a big role in the survival of aggressive cancer cells that are caused by viruses, the LSU research group’s paper said.
They focus on a type of lymphoma called primary effusion lymphoma which is deadly and usually found in HIV patients. In the past, developing effective therapies to treat virus-caused lymphomas has been difficult, but they have seen a change in this with the development of a molecule called ABC294649.
The ABC294649 molecule developed by Apogee Biotechnology Corporation, has proven to have anti-tumor effects within the kidney, prostate and breast cells. It has also not only inhibited Sphingolipids, but it has been a key factor in killing primary effusion lymphoma cells. The drug has been shown to spare the uninfected cells while killing the infected cells.
“This is a major potential advance. There are no therapies available to fight viral tumors by selectively blocking these pathways, all while not harming normal, uninfected cells,” said Dr. Christopher Parsons, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans and senior author of the paper reporting this new research.